Jaguar Gene Therapy

Jaguar Gene Therapy, LLC, founded in 2019, is dedicated to accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. With a team of experts possessing unparalleled CMC (Chemistry, Manufacturing and Controls), regulatory, clinical, and commercial acumen, Jaguar Gene Therapy is committed to patient safety and product purity. The company is rapidly advancing an initial pipeline of three programs targeting: 1) Type 1 galactosemia; 2) a genetic cause of autism spectrum disorder and Phelan-McDermid syndrome with a SHANK3 mutation or deletion; and 3) Type 1 diabetes. Moreover, Jaguar Gene Therapy continues to evaluate opportunities to expand its pipeline using the strength of the team and close relationships with numerous academic institutions. The company's recent Venture Round investment at 29 March 2022 was made by T1D Fund and Samsung Ventures. Positioned within the Biotechnology industry and headquartered in the United States, Jaguar Gene Therapy is gaining attention for its commitment to addressing severe genetic diseases and its potential to provide groundbreaking gene therapy solutions for a sizable patient population.